Ucb: Lower Standards Inward Belgium

The lastly 2 posts on this weblog item how - for all practical purposes - UCB (the large Belgian pharmaceutical company) has lost the patent to i of its principal drugs (Vimpat) too non told the market. See here and here. 

EBIT is probable to autumn 30-40 percentage eventually. The companionship mightiness dain i 24-hour interval to fill upward shareholders inwards on the details. The numbers are actually non pretty but without proper companionship disclosure it is impossible to brand an accurate estimate. 

For virtually 2 weeks I convey expected the UCB to brand a statement. But they convey kept soundless failing to divulge fundamental information to the market.

The patent's piece of work out certificate was solely sent past times the U.S. Patent too Trademark constituent lastly Mon too in that location are dissimilar time-zones too languages to bargain with. So I drafted the blog-posts gently, expecting a confirming press unloosen along alongside accurate arguing of prognosis from the company.

The patents piece of work out certificate is notwithstanding virtually sure enough final. This is a clear arguing of fact past times the Patent Office against the patent. Appeals against patents are virtually ever on matters of constabulary - too courts are reluctant to overturn fact-finders. All previous actions against this patent convey been on law. H5N1 finding of fact against UCB is devastating. 

This is non ordinary course of report of work concern patent litigation. In the ordinary course of report of work concern UCB has injure upward inwards patent disputes alongside other companies (eg Mylan, Argentum). And those disputes convey been where the supposition is that UCB has a valid patent.

This fourth dimension it is inwards dispute alongside the U.S. of A. Government. And the U.S. of A. Government is stating in that location is no valid patent. 

Ask other European companies how disputes alongside the U.S. of A. Government pan out.

Moreover the burden of proof has changed. UCB right away has to instruct its patent approved nether de-novo standards when the Patent Office has already rejected the patent. 

Of course of report none of this seems to warrant whatever arguing from UCB.

Lower standards

I am going to live blunt. Withholding a slice of information this meaning from the marketplace position inwards the U.S. of A. would lawsuit inwards a fairly nasty SEC research consummate alongside subpoenas to hit upward one's heed who knew what too when. I convey made relatively few investments inwards Kingdom of Belgium then I can't order whether the Belgian regulatory standards are lower or the standards are only lower at UCB.

But standards are real depression here.

In the U.S. of A. if a unmarried insider has sold whilst inwards possession of this information (which was unreleased to the market) they could hold back unopen investigation by Preet Bharara. I don't know what standards utilize inwards Belgium.

As stated inwards previous postsI constitute the IR officers nosotros met of real high integrity. But this has to extend higher than this. I intend it has to rising to the grade of Jean-Christophe Tellier - the good regarded CEO.

The Jean-Christophe Tellier was described inwards the press unloosen announcing his appointment as playing "a fundamental role inwards driving the increment of UCB’s 3 center medicines, Cimzia®, Vimpat® too Neupro®."

Presumably he knows that his strategy surrounding those drugs is dead. Presumably he is constituent of withholding that information from the market.

In the U.S. of A. his days equally CEO would live numbered.

I tin solely presume that standards are lower inwards Belgium. But if UCB claims to convey high standards Mr Tellier should live fired.

John